Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apabetalone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 known ✓ | O60885 | 13/20 | 0.84 |
| ▸ | BRD2 known ✓ | P25440 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.75 |
| ▸ | IL17A | Q16552 | 1/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.73 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.73 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.73 |
| ▸ | PARP1 | P09874 | 2/20 | 0.71 |
| ▸ | BRD1 | O95696 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apabetalone SCHEMBL29352238 | 1.00 | BRD4 (0.84) | BRD4HDAC1IL17AHDAC3HDAC4 | |
| SCHEMBL377925 | 0.96 | BRD4 (0.77) | BRD4HDAC1IL17AHDAC3HDAC4 | |
| SCHEMBL30434328 | 0.95 | BRD4 (0.77) | BRD4HDAC1IL17AHDAC3HDAC4 | |
| SCHEMBL122790 | 0.95 | BRD4 (0.77) | BRD4HDAC1IL17AHDAC3HDAC4 | |
| SCHEMBL17930617 | 0.92 | BRD4 (0.74) | BRD4HDAC1IL17AHDAC3HDAC4 | |
| SCHEMBL30052937 | 0.92 | BRD4 (0.74) | BRD4HDAC1IL17AHDAC3HDAC4 | |
| SCHEMBL347354 | 0.92 | BRD4 (0.74) | BRD4HDAC1IL17AHDAC3HDAC4 | |
| Apabetalone SCHEMBL15419059 | 0.91 | BRD4 (0.69) | BRD4HDAC1IL17AHDAC3HDAC4 | |
| SCHEMBL23442956 | 0.91 | BRD4 (0.73) | BRD4HDAC1IL17AHDAC3HDAC4 | |
| SCHEMBL146056 | 0.91 | BRD4 (0.73) | BRD4HDAC1IL17AHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551484-B2 | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | RESVERLOGIX CORP. (CA) | 2026-02-17 | — | — | US | claimed |
| EP-4054584-B1 | METHODS OF TREATMENT AND/OR PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM DEPENDENT GLUCOSE TRANSPORT 2 INHIBITOR | RESVERLOGIX CORP (CA) | 2025-07-09 | — | — | EP | claimed |
| US-20230398137-A1 | METHODS FOR LOWERING HBA1C LEVEL WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM DEPENDENT GLUCOSE TRANSPORT 2 INHIBITOR | RESVERLOGIX CORP. (CA) | 2023-12-14 | — | — | US | claimed |
| US-20230381178-A1 | METHODS FOR IMPROVING RENAL FUNCTION WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM DEPENDENT GLUCOSE TRANSPORT 2 INHIBITOR | RESVERLOGIX CORP. (CA) | 2023-11-30 | — | — | US | claimed |
| EP-3468559-B1 | METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-11-22 | — | — | EP | claimed |
| US-20230310452-A1 | BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS | MDI BIOLOGICAL LABORATORY (US) | 2023-10-05 | — | — | US | claimed |
| EP-4236957-A1 | METHODS FOR LOWERING HBA1C LEVEL WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM DEPENDENT GLUCOSE TRANSPORT 2 INHIBITOR | Resverlogix Corp. (CA) | 2023-09-06 | — | — | EP | claimed |
| EP-4236955-A1 | METHODS FOR IMPROVING RENAL FUNCTION WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM DEPENDENT GLUCOSE TRANSPORT 2 INHIBITOR | Resverlogix Corp. (CA) | 2023-09-06 | — | — | EP | claimed |
| US-20230241064-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A DIPEPTIDYL PEPTIDASE 4 INHIBITOR | RESVERLOGIX CORP (CA) | 2023-08-03 | — | — | US | claimed |
| CN-116390721-A | Methods for improving renal function with a combination of a BET bromodomain inhibitor and a sodium-dependent glucose transport 2 inhibitor | 雷斯韦洛吉克斯公司 | 2023-07-04 | — | — | CN | claimed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | claimed |
| US-8114995-B2 | Methods of preparing quinazolinone derivatives | RESVERLOGIX CORP. (CA) | 2012-02-14 | — | — | US | claimed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | claimed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | claimed |
| JP-2011526287-A | — | — | 2011-10-06 | — | — | JP | claimed |
| EP-2346837-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2011-07-27 | — | — | EP | claimed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | claimed |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2010-01-07 | — | — | US | claimed |
| WO-2009158404-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2009-12-30 | — | — | WO | claimed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241064-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A DIPEPTIDYL PEPTIDASE 4 INHIBITOR | DPP4, BRD4, DPP3 | BRD4 2/4885BRD2 16/4885HDAC1 41/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885BRD2 2769/4885HDAC1 510/4885 |
| US-12551484-B2 | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | SLC5A2, SLC5A1, BRD4 | BRD4 3/4885BRD2 23/4885HDAC1 383/4885 |
| US-20230381178-A1 | METHODS FOR IMPROVING RENAL FUNCTION WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM DEPENDENT GLUCOSE TRANSPORT 2 INHIBITOR | SLC5A2, SLC5A1, BRD4 | BRD4 3/4885BRD2 6/4885HDAC1 167/4885 |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | APOB, APOL1, LDLR | BRD4 1306/4885BRD2 1869/4885HDAC1 1369/4885 |
| US-20230398137-A1 | METHODS FOR LOWERING HBA1C LEVEL WITH A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM DEPENDENT GLUCOSE TRANSPORT 2 INHIBITOR | BRD4, SLC5A2, SLC5A1 | BRD4 1/4885BRD2 5/4885HDAC1 192/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | BRD4 693/4885BRD2 1229/4885HDAC1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.